As of the latest Form 4 filed Feb 13, 2026.
What Enanta Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 25 most recent filings for ENTA.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-02-13 | 2026-02-12 | Kowalsky Matthew Paul Chief Legal Officer | FTax | −1.90K | $14.25 | $27.1K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Kowalsky Matthew Paul, Chief Legal Officer | AAward | +4.17K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Kowalsky Matthew Paul, Chief Legal Officer | AAward | +1.32K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Luu Brendan Chief Business Officer | FTax | −3.26K | $14.25 | $46.4K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Luu Brendan, Chief Business Officer | AAward | +4.99K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Luu Brendan, Chief Business Officer | AAward | +1.57K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Kieffer Tara Lynn Chief Product Strategy Officer | FTax | −3.26K | $14.25 | $46.4K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Kieffer Tara Lynn, Chief Product Strategy Officer | AAward | +4.99K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Kieffer Tara Lynn, Chief Product Strategy Officer | AAward | +1.57K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Rottinghaus Scott T. Chief Medical Officer | FTax | −3.41K | $14.25 | $48.6K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Rottinghaus Scott T., Chief Medical Officer | AAward | +5.22K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Rottinghaus Scott T., Chief Medical Officer | AAward | +1.65K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Or Yat Sun Chief Scientific Officer | FTax | −3.41K | $14.25 | $48.6K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Or Yat Sun, Chief Scientific Officer | AAward | +5.22K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Or Yat Sun, Chief Scientific Officer | AAward | +1.65K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Luly Jay R. President and CEO | FTax | −6.16K | $14.25 | $87.7K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Luly Jay R., President and CEO | AAward | +15.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Luly Jay R., President and CEO | AAward | +4.80K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-05 | 2025-12-05 | Capps Kathleen S. See Remarks | SSale | −323.00 | $14.23 | $4.60K | No | Form 4 ↗ |
| 2025-12-05 | 2025-12-05 | Trout Harry R. III See Remarks | SSale | −542.00 | $14.23 | $7.71K | No | Form 4 ↗ |
| 2025-12-05 | 2025-12-05 | Rottinghaus Scott T. Chief Medical Officer | SSale | −798.00 | $14.23 | $11.4K | No | Form 4 ↗ |
| 2025-12-05 | 2025-12-05 | Luu Brendan Chief Business Officer | SSale | −1.39K | $14.23 | $19.8K | No | Form 4 ↗ |
| 2025-12-05 | 2025-12-05 | Kieffer Tara Lynn Chief Product Strategy Officer | SSale | −2.11K | $14.23 | $30.0K | No | Form 4 ↗ |
| 2025-12-05 | 2025-12-05 | Or Yat Sun Chief Scientific Officer | SSale | −2.39K | $14.23 | $34.0K | No | Form 4 ↗ |
| 2025-12-05 | 2025-12-05 | Luly Jay R. President and CEO | SSale | −4.74K | $14.23 | $67.5K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ENTA’s full analysis or the market-wide insider trading feed. The tabs above jump to ENTA’s other SEC data.
Source: SEC Form 4 filings for ENTA, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.